Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weller

Showing results (801-810 of 831) with videos related to

Pageof 84
Sort By:
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Biorxiv : the Preprint Server for Biology|August 23, 2023
Epigenetic neural glioblastoma enhances synaptic integration and predicts therapeutic vulnerabilityRichard Drexler, Robin Khatri, Thomas Sauvigny, et al.
Neuro-Oncology|April 29, 2021
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, et al.
Acta Neuropathologica|April 25, 2018
Novel, improved grading system(s) for IDH-mutant astrocytic gliomasMitsuaki Shirahata, Takahiro Ono, Damian Stichel, et al.
Neuro-Oncology|August 30, 2025
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy ConsortiumChetan Bettegowda, Houtan Noushmehr, Alessandra Affinito, et al.
Neuro-Oncology|April 25, 2020
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directionsPatrick Y Wen, Michael Weller, Eudocia Quant Lee, et al.
Nature Medicine|May 17, 2024
A prognostic neural epigenetic signature in high-grade gliomaRichard Drexler, Robin Khatri, Thomas Sauvigny, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419)Caroline Hertler, Jörg Felsberg, Dorothee Gramatzki, et al.
Pageof 84

Showing results (801-810 of 831) with videos related to

Sort By:
Pageof 84
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Biorxiv : the Preprint Server for Biology|August 23, 2023
Epigenetic neural glioblastoma enhances synaptic integration and predicts therapeutic vulnerabilityRichard Drexler, Robin Khatri, Thomas Sauvigny, et al.
Neuro-Oncology|April 29, 2021
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, et al.
Acta Neuropathologica|April 25, 2018
Novel, improved grading system(s) for IDH-mutant astrocytic gliomasMitsuaki Shirahata, Takahiro Ono, Damian Stichel, et al.
Neuro-Oncology|August 30, 2025
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy ConsortiumChetan Bettegowda, Houtan Noushmehr, Alessandra Affinito, et al.
Neuro-Oncology|April 25, 2020
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directionsPatrick Y Wen, Michael Weller, Eudocia Quant Lee, et al.
Nature Medicine|May 17, 2024
A prognostic neural epigenetic signature in high-grade gliomaRichard Drexler, Robin Khatri, Thomas Sauvigny, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419)Caroline Hertler, Jörg Felsberg, Dorothee Gramatzki, et al.
Pageof 84